EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Philadelphia chromosome positive chronic phase chronic myelogenous leukemia with pegylated interferon alpha 2B and low-dose cytosine arabinoside



Treatment of Philadelphia chromosome positive chronic phase chronic myelogenous leukemia with pegylated interferon alpha 2B and low-dose cytosine arabinoside



Blood 98(11 Part 2): 258b, November 16



From January 2000 through January 2001, 76 patients (pts) with Ph+CML in early chronic phase were treated with Peg-IFN 6 mcg/kg SQ weekly (24 pts) or 4.5 mcg/kg SQ weekly (52 pts), and ara-C 10 mg SQ daily. Their median age was 49 years (23 to 77); risk group: good 20 (26%), intermediate 23 (36%), poor 11 (14%). Splenomegaly was present in 18 (24%), Hgb<12g/dl in 33 (43%), WBC>50X109/L in 6 (8%), platelets >450X109/L in 20 (26%). Median follow up is 60 weeks (13 to 81). 59 (78%) pts achieved CHR; 45 (59%) had cytogenetic (CG) responses (Phltoreq90%): complete (Ph 0%) in 16 (21%), partial (Phltoreq35%) in 13 (17%). 75 pts are alive, the estimated 2-yr. survival rate was 98%. 20 pts remain on therapy, 56 are off: change to STI571 15; toxicity 23, resistant 16, others 2. The 39 pts with toxicity or resistance were subsequently treated with STI571 (22), bone marrow transplantation (3), homoharringtonine (3), farnesyl transferase inhibitors (2), hydroxyurea (2). 3 patients in blastic phase were treated with STI571 and 2 with combination hyperCVAD and STI571. Grade 3-4 nonhematologic toxicity was 61%: CNS 17%; others (mainly fatigue and aches) 44%. The median Peg-IFN dose delivered was 3.25 mcg/kg. Hgb>12 g/dL or more and absence of peripheral blood blasts were associated with major cytogenetic responses. We conclude that 1) Peg-IFN+ara-C combination produces acceptable response rates in Ph+CML early chronic phase; 2) the Peg-IFN dose of 6 mcg/kg SQ weekly combined with ara-C is associated with significant CNS toxicities and fatigue. The recommended dose of Peg-IFN in combination with ara-C is 3 mcg/kg SQ weekly.

(PDF 0-2 workdays service: $29.90)

Accession: 035980576

Download citation: RISBibTeXText



Related references

Treatment of Philadelphia chromosome -positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low dose cytosine arabinoside. Blood 92(10 SUPPL 1 PART 1-2): 246B, Nov 15, 1998

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer 97(12): 3010-3016, 2003

Interferon alpha and low-dose cytosine arabinoside therapy in Philadelphia chromosome -positive chronic myelogenous leukemia. Blood 86(10 SUPPL 1): 529A, 1995

Homoharringtonine and low-dose cytosine arabinoside is effective and safe for the treatment of Philadelphia chromosome -positive late chronic phase chronic myelogenous leukemia. Blood 92(10 SUPPL 1 PART 1-2): 246B, Nov 15, 1998

Treatment of philadelphia chromosome positive ph positive chronic myelogenous leukemia in blast crisis and ph positive acute leukemia with high dose cytosine arabinoside hdarac. Leukemia & Lymphoma 4(2): 111-116, 1991

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. Journal of Clinical Oncology 17(1): 284-292, 1999

Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC). Leukemia & Lymphoma 4(2): 111-116, 1991

Homoharringtonine and low-dose cytosine arabinoside combination therapy has significant activity in patients with late phase Philadelphia chromosome - positive chronic myelogenous leukemia. Blood 88(10 SUPPL 1 PART 1-2): 578A, 1996

Triple combination therapy with interferon-alpha , low-dose cytarabine and homoharringtonine in Philadelphia chromosome -positive chronic myelogenous leukemia in early chronic phase. Blood 94(10 SUPPL 1 PART 2): 275b, Nov 15, 1999

The treatment of chronic myelogenous leukemia in chronic phase with interferon alpha and cytosine-arabinoside Results of the French trials. Journal of Molecular Medicine (Berlin) 75(7): B236-B237, 1997

Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group. Seminars in Hematology 30(3 Suppl 3): 24-25, 1993

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. Journal of Clinical Oncology 10(5): 772-778, 1992

Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside. Leukemia Research 17(8): 711-715, 1993